PuSH - Publikationsserver des Helmholtz Zentrums München: Variability of forced vital capacity in progressive interstitial lung disease: A prospective observational study.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Veit, T. ; Barnikel, M. ; Crispin, A.* ; Kneidinger, N. ; Ceelen, F. ; Arnold, P. ; Munker, D. ; Schmitzer, M. ; Barton, J. ; Schiopu, S. ; Schiller, H. B. ; Frankenberger, M. ; Milger, K. ; Behr, J. ; Neurohr, C.* ; Leuschner, G.

Variability of forced vital capacity in progressive interstitial lung disease: A prospective observational study.

Respir. Res. 21:270 (2020)

Verlagsversion

DOI

PMC

	Open Access Gold

Abstract
Metriken
Zusatzinfos

BackgroundFibrotic interstitial lung disease (ILD) is often associated with poor outcomes, but has few predictors of progression. Daily home spirometry has been proposed to provide important information about the clinical course of idiopathic pulmonary disease (IPF). However, experience is limited, and home spirometry is not a routine component of patient care in ILD. Using home spirometry, we aimed to investigate the predictive potential of daily measurements of forced vital capacity (FVC) in fibrotic ILD.MethodsIn this prospective observational study, patients with fibrotic ILD and clinical progression were provided with home spirometers for daily measurements over 6 months. Hospital based spirometry was performed after three and 6 months. Disease progression, defined as death, lung transplantation, acute exacerbation or FVC decline >10% relative was assessed in the cohort.ResultsFrom May 2017 until August 2018, we included 47 patients (IPF n=20; non-IPF n=27). Sufficient daily measurements were performed by 85.1% of the study cohort. Among these 40 patients (IPF n=17; non-IPF n=23), who had a meanSD age of 60.7 +/- 11.3years and FVC 64.7 +/- 21.7% predicted (2.4 +/- 0.8L), 12 patients experienced disease progression (death: n= 2; lung transplantation: n=3; acute exacerbation: n=1; FVC decline >10%: n=6). Within the first 28days, a group of patients had high daily variability in FVC, with 60.0% having a variation >= 5%. Patients with disease progression had significantly higher FVC variability than those in the stable group (median variability 8.6% vs. 4.8%; p=0.002). Cox regression identified FVC variability as independently associated with disease progression when controlling for multiple confounding variables (hazard ratio: 1.203; 95% CI:1.050-1.378; p=0.0076).Conclusions Daily home spirometry is feasible in IPF and non-IPF ILD and facilitates the identification of FVC variability, which was associated with disease progression.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

3.924

1.137